CUPR is trading at $6.26, down 5% in pre-market as investors take profits following a significant rally triggered by FDA 510(k) clearance for its Medifly Maggots wound-care therapy.
- The stock surged approximately 48% on June 30 and extended gains in after-hours trading before the current retracement.
- The pullback appears to be a company-specific technical move, as broader market indices and crypto markets are only seeing modest declines.